#United States #Class Action #Radnor #Ultragenyx #RARE

Ultragenyx Pharmaceutical Inc. Faces Class Action Lawsuit

Ultragenyx Pharmaceutical Inc., publicly traded under the ticker symbol RARE, is currently the subject of a securities fraud class action lawsuit. This legal action is poised to potentially affect numerous investors who bought common stock during the defined class period, which spans from August 3, 2023, to December 26, 2025. The upcoming deadline for affected investors to seek lead plaintiff status is set for April 6, 2026.

Overview of the Class Action Suit

The lawsuit, filed in the United States District Court for the Northern District of California, is marked as Bailey v. Ultragenyx Pharmaceutical Inc., et al, Case No. 326-cv-01097 (N.D. Cal.). Those who had purchased Ultragenyx stocks within the specified timeframe are being urged to take action, especially if they have witnessed financial losses due to their investments.

The primary allegations center around material misstatements and omissions regarding the company's drug, setrusumab. The complaint asserts that Ultragenyx misled investors regarding the effectiveness of setrusumab in treating Osteogenesis Imperfecta, suggesting that the company did not adequately communicate the risks associated with the drug's Phase III clinical trials, particularly the Orbit study. The lawsuit points to a significant decline in the company's stock price following public disclosures regarding the clinical trial outcomes, further evidencing the impact of these alleged misrepresentations.

The Impact of the Allegations on Investors

On December 29, 2025, Ultragenyx's stock experienced a staggering drop of over 42%. This decline followed the company's announcement that both the Phase III Orbit and Cosmic studies failed to meet the primary endpoints of meaningful reduction in the annualized clinical fracture rate when measured against both placebo and standard care treatments. This abrupt revelation highlighted the disconnect between the optimistic projections posed by the company in prior statements and the real results observed in their clinical studies.

Investor Steps Moving Forward

Affected investors now have several options on how to proceed. They can file to be a lead plaintiff by the April 6, 2026 deadline, which presents an opportunity to directly influence the direction of the lawsuit. Alternatively, investors may reach out to Kessler Topaz Meltzer & Check, LLP (KTMC), which is representing numerous investors in this matter, for a free case evaluation. It is crucial to understand that investors are not required to take any action to remain eligible for any recovery that may emerge from the lawsuit, but those interested can select their own legal counsel or allow KTMC to direct their representation.

About Kessler Topaz Meltzer & Check, LLP

KTMC is a well-respected law firm specializing in securities-fraud class action lawsuits and global investor protection. They have a robust track record in recovering substantial amounts for defrauded investors and have received numerous accolades for their work in litigating these cases. With offices in Pennsylvania and California, KTMC is uniquely positioned to assist investors facing such challenges. They have successfully recovered over $25 billion for their clients over the years.

For more information, investors are encouraged to visit the firm's website at KTMC's Website. If you have suffered losses due to your investment in Ultragenyx, initiating contact with legal professionals may provide you with the recovery options available to you at no cost.

Conclusion

Ultragenyx Pharmaceutical Inc.'s current class action lawsuit underscores the importance of transparency in corporate communications, as well as the potential repercussions when investors are not adequately informed. As the April 2026 deadline approaches, affected investors should carefully assess their options and consider legal avenues to pursue recompense for their losses stemming from this significant corporate event.